CD34 is a glycosylated transmembrane protein and represents a well-established marker for human hematopoietic stem and progenitor cells in peripheral blood, bone marrow, and cord blood. CD34+ cells are self-renewing, multipotent stem cells that give rise to all blood cells of the immune system through a process called hematopoiesis. As hematopoietic stem cells progress through hematopoiesis they generate the myeloid (monocytes, macrophages, granulocytes, megakaryocytes, dendritic cells, erythrocytes) and lymphoid (T cells, B cells, NK cells) lineages. The highly specialized cells that arise from hematopoietic stem cells work collaboratively in defending the body against infection and disease.

Human cord blood CD34+ stem and progenitor cells are positively selected using immunomagnetic anti-CD34 (clone QBEND10) microbeads from the mononuclear cell fraction. Isolated cells are characterized by flow cytometry prior to cryopreservation to ensure a highly pure and viable cell population.

Cord blood is collected from mothers that are negative for HIV, HepB, and HepC during pregnancy. Infectious disease testing, LCMV testing, and HLA typing on the cord blood can be provided as a custom order.

Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.